

MATRIXYL®3000



Pal-GHK and Pal-GQPR



Function:

Anti-wrinkle.

Definition:

Association of 2 palmitoylated matrikines: Pal-Gly-His-Lys and Pal-Gly-Gln-Pro-Arg.

Properties:

Matrixyl®3000 supports the activation of the cutaneous repair process, and in particular at the level of the fragile and UV-damage prone papillary dermis. Matrixyl®3000 promotes wrinkle smoothing and improves tone and elasticity.

Characteristics:

Matrikines are messenger peptides capable of regulating cell activities by interacting with their specific receptors. They activate certain genes involved in the process of extracellular matrix renewal and cell proliferation. These mechanisms become weaker and weaker with age.

Point of interest:

Matrixyl®3000 regulates the expression of progerin, a senescence marker known to accumulate with age, whereas it maintains its normal form lamin A.

INCI Name:

- Glycerin Aqua (Water) -
- Butylene Glycol Carbomer -
- Polysorbate 20 Palmitoyl Tripeptide-1*
 - Palmitoyl Tetrapeptide-7

Preservatives free

*former INCI name: Palmitoyl Oligopeptide

Applications:

Anti-wrinkle products.

Formulation:

Water soluble.

Recommended use level:

3%

Patent:

FR 2 975 904, EP 1 686 957, WO 2012/164488, WO 2005/048968, US,6,974,799, JP 4256389, CN1893911, KR 2006-0122844



www.sederma.com E-mail: sederma@sederma.fr Copyright@ 2000-2015



Ex vivo tests

Quantification of constituent, anchorage and cohesion proteins of the dermis and dermal-epidermal junction on skin explants (n=10, from 30 to 66 years).


In vitro tests

REGULATION OF SENESCENCE MARKERS

Study on senescent fibroblasts with Matrixyl®3000 eg 5%

• SA β-galactosidase (fluorescence method)-56%, p<0.01</td>• Progerin (RNA expression)-27%, p<0.05</td>Lamin A (RNA expression)+4%, ns





In vivo tests

REPAIR OF THE PAPILLARY DERMIS

28 female volunteers aged from 51 to 72 years, mean age 59. Twice daily application of a cream containing 3% of Matrixyl®3000 for 2 months to one half of the face and the forearm (inner and UV-exposed outer forearm) against placebo.

ANALYSIS OF THE Subepidermal Low Echogenicity Band

| | after 2 months | Inner forearm | Outer forearm |
|--|----------------|---|--|
| | THICKNESS | -9.8%/T0 up to -23% , p<0.01 | -9.8%/T0 up to -33% , p<0.01 |
| | | 93% volunteers | 86% volunteers |
| | | -11%/placebo, p<0.01 | -14.4%/placebo, p<0.01 |
| | DENSITY | +11.4%/T0 up to +44% , p<0.01 | +11.5%/T0 up to +45%, p<0.01 |
| | | 68% volunteers | 82% volunteers |
| | | +15.2%/placebo , p<0.01 | +15.1%/placebo, p<0.01 |
| | AGE GAIN | -3.8 years | -5.5 years |






Significant improvement of the SLEB characteristics in just one month (thickness: -5.5%/placebo; density: +7.8%/placebo, on the inner arm) and confirmed after two months. The ageing process is slowed down by 1.8 years in just one month.

ANALYSIS OF THE FIBRE NETWORK

Measurements of the fibre defragmentation by confocal laser microscopy (Vivascope) on the face, next to the external eye corner.







+13.9%/T0
up to +54%
p<0.01
71% volunteers had an improvement



Matrixyl®3000 helps reduce the fibre fragmentation and notably supports the reconstruction of the papillary dermal fibre network.

ANTI-WRINKLE EFFICACY, SKIN TONE AND ELASTICITY

23 female volunteers aged from 42 to 67 years / Twice daily application on one half of the face of a cream containing 3% of Matrixyl®3000 against placebo, for 2 months. Assessment of the anti-wrinkle efficacy by profilometry, cutometry and photography compared to TO.

| Compared to TO (%) | Matrixyl®3000 | Placebo |
|-----------------------------------|---------------|---------|
| Surface occupied by deep wrinkles | - 39.4** | 4.3ns |
| Main wrinkle density | - 32.9** | - 9.9ns |
| Main wrinkle average depth | - 19.9** | - 3.2ns |
| Main wrinkle average volume | - 23.3** | - 8.7* |
| Roughness | - 16.0** | - 1.4ns |
| Complexity (Lifting effect) | - 16.2** | 4.2ns |
| Elasticity | +5.5* | 4.1ns |
| Skin tone | +15.5** | 6.5ns |

*significant/T0 (p<0.05)





The repairing effect of Matrixyl®3000 promotes the visible quality of the skin by decreasing the appearance of wrinkles and improving tone and elasticity.



Non-warranty: The information in this publication is believed to be accurate and is given in good faith, but no representation or warranty as to its completeness or accuracy is made. Suggestions for uses or applications are only opinions. Users are responsible for determining the suitability of these products for their own particular purpose. No representation or warranty, expressed or implied, is made with respect to information or products including, without limitation, warranties of merchantability, fitness for a particular purpose, non-infringement of any third party patent or other intellectual property rights including, without limit, copyright, trademark and designs. Any trademarks identified herein, unless otherwise noted, are trademarks of the Croda group of companies. ©2015 Sederma is strictly prohibited.

Reproduction of all or part of this document without the express prior written consent of Sederma is strictly prohibited.

**significant/T0 (p<0.01)

ns: non significant